KURN Relative Valuation - Kuros Biosciences AG - Alpha Spread

Kuros Biosciences AG
SIX:KURN

Watchlist Manager
Kuros Biosciences AG Logo
Kuros Biosciences AG
SIX:KURN
Watchlist
Price: 22.05 CHF 11.25%
Market Cap: 807.1m CHF
Have any thoughts about
Kuros Biosciences AG?
Write Note

Relative Value

The Relative Value of one KURN stock under the Base Case scenario is 6.12 CHF. Compared to the current market price of 22.05 CHF, Kuros Biosciences AG is Overvalued by 72%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

KURN Relative Value
Base Case
6.12 CHF
Overvaluation 72%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
34
vs Industry
40
Median 3Y
4.5
Median 5Y
6.8
Industry
7.9
vs History
vs Industry
Median 3Y
-8.3
Median 5Y
-5.7
Industry
23.3
vs History
vs Industry
Median 3Y
-11.7
Median 5Y
-7.3
Industry
22.8
vs History
vs Industry
Median 3Y
-10.3
Median 5Y
-6.8
Industry
26.4
vs History
0
vs Industry
11
Median 3Y
0.8
Median 5Y
0.8
Industry
2.6
vs History
12
vs Industry
35
Median 3Y
2.7
Median 5Y
5.5
Industry
7.6
vs History
26
vs Industry
30
Median 3Y
4.1
Median 5Y
7.4
Industry
9
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-5.1
Industry
4.7
vs History
vs Industry
Median 3Y
-4.2
Median 5Y
-3.9
Industry
4.3
vs History
vs Industry
Median 3Y
-7.5
Median 5Y
-4.6
Industry
6.4
vs History
vs Industry
Median 3Y
-7.1
Median 5Y
-4.6
Industry
4.2
vs History
0
vs Industry
25
Median 3Y
0.7
Median 5Y
0.6
Industry
4.7

Multiples Across Competitors

KURN Competitors Multiples
Kuros Biosciences AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Kuros Biosciences AG
SIX:KURN
797.8m CHF 15.2 -91.2 -119.5 -85.6
US
Abbvie Inc
NYSE:ABBV
345.5B USD 6.3 65.2 15.9 24.4
US
Amgen Inc
NASDAQ:AMGN
174.7B USD 5.6 55.8 19.7 35.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.4B USD 12 -254.1 27 28.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
113.3B USD 8.4 26.2 22.8 25.3
US
Gilead Sciences Inc
NASDAQ:GILD
105.3B USD 3.8 100 9.5 12.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 941.9 -495.5 -539.6 -525.2
AU
CSL Ltd
ASX:CSL
144.6B AUD 6.6 36.9 22.6 28.1
US
Seagen Inc
F:SGT
39.3B EUR 18.7 -57.4 -61.7 -55.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
36.4B USD 15.5 -499.5 220.2 339
KY
Beigene Ltd
SSE:688235
246.7B CNY 11.1 -56.4 -35 -35
P/E Multiple
Earnings Growth
CH
Kuros Biosciences AG
SIX:KURN
Average P/E: 56.8
Negative Multiple: -91.2
N/A
US
Abbvie Inc
NYSE:ABBV
65.2
406%
US
Amgen Inc
NASDAQ:AMGN
55.8
74%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -254.1
38%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
26.2
56%
US
Gilead Sciences Inc
NASDAQ:GILD
100
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -495.5 N/A
AU
CSL Ltd
ASX:CSL
36.9
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.4 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -499.5 N/A
KY
Beigene Ltd
SSE:688235
Negative Multiple: -56.4 N/A
EV/EBITDA Multiple
EBITDA Growth
CH
Kuros Biosciences AG
SIX:KURN
Average EV/EBITDA: 48.2
Negative Multiple: -119.5
N/A
US
Abbvie Inc
NYSE:ABBV
15.9
28%
US
Amgen Inc
NASDAQ:AMGN
19.7
64%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27
37%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
22.8
53%
US
Gilead Sciences Inc
NASDAQ:GILD
9.5
9%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -539.6 N/A
AU
CSL Ltd
ASX:CSL
22.6
42%
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.7 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
220.2
N/A
KY
Beigene Ltd
SSE:688235
Negative Multiple: -35 N/A
EV/EBIT Multiple
EBIT Growth
CH
Kuros Biosciences AG
SIX:KURN
Average EV/EBIT: 70.4
Negative Multiple: -85.6
N/A
US
Abbvie Inc
NYSE:ABBV
24.4
88%
US
Amgen Inc
NASDAQ:AMGN
35.7
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.4
44%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
25.3
54%
US
Gilead Sciences Inc
NASDAQ:GILD
12.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.2 N/A
AU
CSL Ltd
ASX:CSL
28.1
55%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.7 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
339
N/A
KY
Beigene Ltd
SSE:688235
Negative Multiple: -35 N/A

See Also

Discover More
Back to Top